DGAP-News

Apricus Biosciences Provides First Quarter 2013 Corporate Update - Seite 3

extravasation, to Biocodex USA ('Biocodex') in March 2013, in line with its
recently updated corporate strategy. Under terms of the arrangement,
Apricus Bio received an upfront payment at closing and is eligible to
receive royalties on net sales of Totect(r) by Biocodex through 2016, in
exchange for Apricus Bio's sale of its commercialization rights to Totect(r)
in North America and South America.

Conference Call Information

The call can be accessed in the U.S. by dialing 877-407-9210 and outside of the
U.S. by dialing 201-689-8049 and asking the conference operator for the Apricus
Bio Conference Call. The conference call will also be webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=17095. The teleconference
replay will be available for one week by dialing in the U.S. 877-660-6853 and
outside of the U.S. by dialing 201-612-7415. Replay Passcode 413843 is required
for playback. The webcast replay will be available for three months.

About Vitaros(r)

Vitaros(r), Apricus Bio's lead product candidate for the treatment of ED, is a
topically-applied cream formulation of alprostadil, a vasodilator, which
directly increases blood flow to the penis, causing an erection. Alprostadil is
a widely accepted alternative to the PDE5 inhibitors for difficult to treat
patients, and Vitaros(r) is relatively safe and effective, and offers greater
market opportunity due to its patient-friendly form versus both other
alprostadil dosage forms and also relative to oral ED products. With a market
affecting nearly 150 million men worldwide and representing approximately $2.6
billion in revenue - excluding the U.S. - Vitaros(r) represents a major market
opportunity, particularly as a distinct product that addresses a significant
underserved population.

About Femprox(r)

Femprox(r) is a product candidate for the treatment of female sexual arousal
disorder (FSAD). Seven clinical studies have been successfully completed to
date, including one, 98-subject Phase 2 study in the US and a nearly
400-subject Phase 3 study in China. To date, no product has been approved in
the U.S. to treat FSAD, a persistent or recurring inability to attain or
maintain adequate sexual excitement, causing personal distress. Estimates of
the FSAD market size put it on par with erectile dysfunction in males, and
possibly larger.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual